Acyte Biotech

Executive Summary

Acyte Biotech is an Australian contract development organization (CDO) specializing in accelerating early-stage biopharmaceutical programs through its proprietary CHO-based cell line platforms, antibody reformatting, and rapid clonal isolation services. Its flagship SuperCHO suite combines high-yielding transient expression with stable CHO line generation, enabling fast, scalable production of therapeutic proteins and antibodies. Founded in 2013 and headquartered in Brisbane, the company serves a growing demand for outsourced bioprocess development, particularly among small and mid-sized biotechs seeking speed and cost-efficiency. With a lean team of 10-50 employees, Acyte positions itself as a flexible, technology-driven partner in the competitive CDO landscape, leveraging its expertise in CHO cell engineering to reduce timelines from gene to gram. The platform's versatility supports a range of modalities, including monoclonal antibodies, bispecifics, and fusion proteins, catering to oncology and immunology-focused clients. As the biopharma industry increasingly prioritizes rapid candidate validation and manufacturing agility, Acyte's service offerings align well with market needs, though its scalability and client diversification remain key to sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded high-throughput antibody screening service70% success
• H2 2026Strategic partnership with a top-20 biopharma company for SuperCHO licensing50% success
• Q1 2027Completion of lab facility expansion to triple production capacity80% success